All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Elias JabbourSteering Committee Member
Elias Jabbour is a professor of medicine in the Department of Leukemia, Division of Cancer Medicine, at the MD Anderson Cancer Center, Houston, US. He received education and training in the US, France, and Lebanon in the fields of hematology, hematology-oncology, and clinical carcinology. He has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others, including the hyper CVAD-ofatumumab regimen in ALL; clofarabine in myeloid malignancies; hypomethylating agents in acute myeloid leukemia (AML) and myelodysplastic syndromes; tyrosine kinase therapy in chronic myeloid leukemia; and triple therapy in AML.